Sobi adds rare lymphoma drug with $580m Innate tie-up

Sobi adds rare lymphoma drug with $580m Innate tie-up

Sobi chief executive Guido Oelkers is preparing his exit, but is still cutting deals, licensing a lymphoma drug from Innate for up to $580m.

Sobi and Innate Pharma License Lacutamab in T-Cell Lymphoma // Cooley // Global Law Firm

Swedish kiss for french Innate: Sobi backs Innate’s lacutamab as rare T-cell lymphoma program enters Phase 3 - European Biotechnology Magazine

Swedish rare-disease specialist Sobi is paying $75 million upfront for global commercial rights to Innate Pharma’s lacutamab, a first-in-class antibody targeting KIR3DL2 in cutaneous T-cell lymphoma. The deal gives Innate funding and a commercial partner for its next clinical step, while adding a late-stage oncology asset to Sobi’s rare-disease portfolio. The post Swedish kiss for french Innate: Sobi backs Innate’s lacutamab as rare T-cell lymph…

Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer

Innate to advance lacutamab towards TELLOMAK-3 Phase 3 following the partnership with Sobi, a key step toward the